RECOMMEND Platform Trial
Recruiting
Phase 3
Interventional Study
Extracorporeal Membrane Oxygenation Complication
ARDS (Acute Respiratory Distress Syndrome)
Intensive Care Medicine
Cardiac Arrest (CA)
Critical Illness
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 600 (estimated)
- Sponsor
- Australian and New Zealand Intensive Care Research Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO)
The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
PLATFORM INCLUSION CRITERIA:
* Patients receiving ECMO
* Patients enrolled in the EXCEL Registry - NCT03793257
PLATFORM EXCLUSION CRITERIA:
* Treating clinician regards death as imminent and inevitable
* Treating clinician determines it is not in the patient's best interests
RBC TRANSFUSION DOMA…
Contacts